Warning letters, 483s, Recalls, Import Alerts, Audit observations
Author: Venkiteswaran.T.K The USFDA’s 2011 guidance on process validation advocates a life cycle approach and
In March 2025, Glenmark initiated recall of 23 products (148 lots) in US for cGMP
Qvents Apps & Tools Access the Excipient Risk Assessment Tool – Click Here According to
Authored by: Srinivas Churya This Quality Insight post presents a concise approach for selection and
Granules India received a warning letter from the USFDA in February 2025. This was along
Janssen’s Korean Vaccine unit Janssen Vaccines Corporation (FEI 3012637764) received an USFDA 483 for critical
Indian API manufacturer Jagsonpal Pharmaceuticals was issued a Warning Letter by the US FDA in
Authored by: Srinivas Churya In the pharmaceutical industry, analytical division and analytical laboratories plays a
Five different facilities of Eugia across India and US were inspected by USFDA between December
The Eugia facility in Bhiwadi, Rajasthan, India (FEI 3009883410) was recently classified as OAI (Official
